Funding round brings in $75M for Ultragenyx

12/21/2012 | North Bay Business Journal (Santa Rosa, Calif.)

Ultragenyx Pharmaceutical secured $75 million in a Series B funding round and will use the money to further develop its lead drug candidates, UX001 and UX003. UX001 is being developed as a replacement therapy for hereditary inclusion body myopathy, while UX003 is an experimental enzyme replacement therapy for mucopolysaccharidosis type 7.

View Full Article in:

North Bay Business Journal (Santa Rosa, Calif.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations